Unbound MEDLINE

Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. Travel medicine and infectious disease [Travel Med Infect Dis] Journal article

 
TitleFailure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon.
Author(s)Gallien S, Taieb F, Schlemmer F, Lagrange-Xelot M, Atlan A, Sarfati C, Molina JM 
InstitutionDepartment of Tropical and Infectious Diseases, Saint-Louis University Hospital, 75475 Paris Cedex 10, France. sebastien_gallien@yahoo.fr
SourceTravel Med Infect Dis 2008 May; 6(3):128-9.
MeSHAged
Animals
Antimalarials
Atovaquone
Cameroon
Chloroguanide
Diagnosis, Differential
Fever
France
Headache
Humans
Malaria
Male
Plasmodium ovale
Travel
AbstractWe report a case of a patient returning from Cameroon who developed Plasmodium ovale malaria, despite atovaquone/proguanil (AP, Malarone) prophylaxis, which is widely used for the prevention of chloroquine-resistant malaria. AP is indeed active only on schizont blood forms of P. ovale but not against liver-stage hypnozoites and does not realize effective prophylaxis against delayed onset of P. ovale malaria. Hence, this case illustrates the risk of failure with Malarone for the prophylaxis of P. ovale infection for travelers in endemic regions. Travelers returned from risk areas with symptoms suggestive of malaria, should not have the diagnosis of P. ovale (or P. vivax) infection discounted, despite a history of compliance with a standard chemoprophylactic regimen.
Languageeng
Pub Type(s)Case Reports
Journal Article
PubMed ID18486067
  
Advertise on this site.